7,909 reports of this reaction
2.8% of all ADALIMUMAB FKJP reports
#2 most reported adverse reaction
OFF LABEL USE is the #2 most commonly reported adverse reaction for ADALIMUMAB FKJP, manufactured by Biocon Biologics Inc. There are 7,909 FDA adverse event reports linking ADALIMUMAB FKJP to OFF LABEL USE. This represents approximately 2.8% of all 281,217 adverse event reports for this drug.
Patients taking ADALIMUMAB FKJP who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is a less commonly reported adverse event for ADALIMUMAB FKJP, but still significant enough to appear in the safety profile.
In addition to off label use, the following adverse reactions have been reported for ADALIMUMAB FKJP:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 7,909 FDA reports for ADALIMUMAB FKJP. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 2.8% of all adverse event reports for ADALIMUMAB FKJP, making it one of the most commonly reported side effect.
If you experience off label use while taking ADALIMUMAB FKJP, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.